Candriam SCA’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-152,187
| Closed | -$572K | – | 890 |
|
|
2023
Q1 | $572K | Sell |
152,187
-223,975
| -60% | -$841K | ﹤0.01% | 757 |
|
|
2022
Q4 | $1.89M | Buy |
376,162
+92,112
| +32% | +$462K | 0.01% | 590 |
|
|
2022
Q3 | $3.72M | Buy |
284,050
+66,863
| +31% | +$875K | 0.03% | 446 |
|
|
2022
Q2 | $2.78M | Hold |
217,187
| – | – | 0.02% | 432 |
|
|
2022
Q1 | $3.31M | Buy |
+217,187
| New | +$3.31M | 0.02% | 433 |
|
|
2021
Q4 | – | Sell |
-564,059
| Closed | -$11.9M | – | 883 |
|
|
2021
Q3 | $11.9M | Hold |
564,059
| – | – | 0.08% | 244 |
|
|
2021
Q2 | $11.1M | Buy |
564,059
+342,425
| +155% | +$6.75M | 0.08% | 272 |
|
|
2021
Q1 | $6.45M | Hold |
221,634
| – | – | 0.05% | 332 |
|
|
2020
Q4 | $6.72M | Sell |
221,634
-7,130
| -3% | -$216K | 0.05% | 341 |
|
|
2020
Q3 | $3.64M | Hold |
228,764
| – | – | 0.03% | 400 |
|
|
2020
Q2 | $4.52M | Sell |
228,764
-13,236
| -5% | -$261K | 0.05% | 355 |
|
|
2020
Q1 | $4.37M | Hold |
242,000
| – | – | 0.05% | 385 |
|
|
2019
Q4 | $4.48M | Buy |
242,000
+87,000
| +56% | +$1.61M | 0.05% | 395 |
|
|
2019
Q3 | $2.15M | Buy |
155,000
+20,000
| +15% | +$277K | 0.03% | 471 |
|
|
2019
Q2 | $1.97M | Buy |
+135,000
| New | +$1.97M | 0.02% | 518 |
|